Role of N6-methyladenosine RNA modification in cancer

被引：6

作者：

Qu, Yi ^{[1
]}

Gao, Nannan ^{[1
]}

Zhang, Shengwei ^{[1
]}

Gao, Limin ^{[1
]}

He, Bing ^{[1
]}

Wang, Chao ^{[1
]}

Gong, Chunli ^{[1
]}

Shi, Qiuyue ^{[2
]}

Li, Zhibin ^{[1
]}

Yang, Shiming ^{[1
]}

Xiao, Yufeng ^{[1
]}

机构：

[1] Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China

[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanning, Guangxi, Peoples R China

来源：

MEDCOMM | 2024年 / 5卷 / 09期

基金：

中国国家自然科学基金;

关键词：

cancer; immunity; m6A; microorganism; posttranslational modification; programmed cell death; TUMOR-ASSOCIATED MACROPHAGES; DEMETHYLASE FTO INHIBITORS; STEM-CELL MAINTENANCE; MESSENGER-RNA; BREAST-CANCER; M6A MODIFICATION; NUCLEAR-RNA; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; TRIGGERS CHEMORESISTANCE;

D O I：

10.1002/mco2.715

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

N6-methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells. Previous studies have shown that m6A is pivotal in diverse diseases especially cancer. m6A corelates with the initiation, progression, resistance, invasion, and metastasis of cancer. However, despite these insights, a comprehensive understanding of its specific roles and mechanisms within the complex landscape of cancer is still elusive. This review begins by outlining the key regulatory proteins of m6A modification and their posttranslational modifications (PTMs), as well as the role in chromatin accessibility and transcriptional activity within cancer cells. Additionally, it highlights that m6A modifications impact cancer progression by modulating programmed cell death mechanisms and affecting the tumor microenvironment through various cancer-associated immune cells. Furthermore, the review discusses how microorganisms can induce enduring epigenetic changes and oncogenic effect in microorganism-associated cancers by altering m6A modifications. Last, it delves into the role of m6A modification in cancer immunotherapy, encompassing RNA therapy, immune checkpoint blockade, cytokine therapy, adoptive cell transfer therapy, and direct targeting of m6A regulators. Overall, this review clarifies the multifaceted role of m6A modification in cancer and explores targeted therapies aimed at manipulating m6A modification, aiming to advance cancer research and improve patient outcomes. N6-methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells. Previous studies have shown that m6A is pivotal in diverse diseases especially cancer. m6A corelates with the initiation, progression, resistance, invasion and metastasis of cancer. However, despite these insights, a comprehensive understanding of its specific roles and mechanisms within the complex landscape of cancer is still elusive. This review begins by outlining the key regulatory proteins of m6A modification and their posttranslational modifications, as well as the role in chromatin accessibility and transcriptional activity within cancer cells. Additionally, it highlights that m6A modifications impact cancer progression by modulating programmed cell death (PCD) mechanisms and affecting the tumor microenvironment through various cancer-associated immune cells. Furthermore, the review discusses how microorganisms can induce enduring epigenetic changes and oncogenic effect in microorganism-associated cancers by altering m6A modifications. Last, it delves into the role of m6A modification in cancer immunotherapy, encompassing RNA therapy, immune checkpoint blockade, cytokine therapy, adoptive cell transfer therapy, and direct targeting of m6A regulators. Overall, this review clarifies the multifaceted role of m6A modification in cancer and explores targeted therapies aimed at manipulating m6A modification, aiming to advance cancer research and improve patient outcomes image .

引用

页数：40

共 403 条

[91] Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis [J].

Hsu, Phillip J. ;

Zhu, Yunfei ;

Ma, Honghui ;

Guo, Yueshuai ;

Shi, Xiaodan ;

Liu, Yuanyuan ;

Qi, Meijie ;

Lu, Zhike ;

Shi, Hailing ;

Wang, Jianying ;

Cheng, Yiwei ;

Luo, Guanzheng ;

Dai, Qing ;

Liu, Mingxi ;

Guo, Xuejiang ;

Sha, Jiahao ;

Shen, Bin ;

He, Chuan .

CELL RESEARCH, 2017, 27 (09) :1115-1127

[92] Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma [J].

Hu, Bowen ;

Gao, Jie ;

Shi, Jihua ;

Zhang, Feng ;

Shi, Chengcheng ;

Wen, Peihao ;

Wang, Zhihui ;

Guo, Wenzhi ;

Zhang, Shuijun .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[93] HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m6A-MYC expression [J].

Hu, Chenchen ;

Liu, Tianyue ;

Han, Chenying ;

Xuan, Yuxin ;

Jiang, Dongbo ;

Sun, Yuanjie ;

Zhang, Xiyang ;

Zhang, Wenxin ;

Xu, Yiming ;

Liu, Yang ;

Pan, Jingyu ;

Wang, Jing ;

Fan, Jiangjiang ;

Che, Yinggang ;

Huang, Yinan ;

Zhang, Jiaxing ;

Ding, Jiaqi ;

Yang, Shuya ;

Yang, Kun .

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (02) :507-521

[94] FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m6A-dependent manner [J].

Hu, Yuhan ;

Gao, Qingzu ;

Ma, Shuai ;

Yu, Pei ;

Ding, Shuang ;

Yao, Xiaofei ;

Zhang, Zheying ;

Lu, Shuya ;

Lu, Manman ;

Zhang, Jinghang ;

Wang, Yanling ;

Qian, Xinlai ;

Zhong, Jiateng .

CELL DEATH & DISEASE, 2022, 13 (11)

[95] Exosome-derived circCCAR1 promotes CD8+T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma [J].

Hu, Zongqiang ;

Chen, Gang ;

Zhao, Yingpeng ;

Gao, Hongqiang ;

Li, Laibang ;

Yin, Yanfeng ;

Jiang, Jie ;

Wang, Li ;

Mang, Yuanyi ;

Gao, Yang ;

Zhang, Shengning ;

Ran, Jianghua ;

Li, Li .

MOLECULAR CANCER, 2023, 22 (01)

[96] Recognition of RNA N6- methyladenosine by IGF2BP proteins enhances mRNA stability and translation [J].

Huang, Huilin ;

Weng, Hengyou ;

Sun, Wenju ;

Qin, Xi ;

Shi, Hailing ;

Wu, Huizhe ;

Zhao, Boxuan Simen ;

Mesquita, Ana ;

Liu, Chang ;

Yuan, Celvie L. ;

Hu, Yueh-Chiang ;

Huettelmaier, Stefan ;

Skibbe, Jennifer R. ;

Su, Rui ;

Deng, Xiaolan ;

Dong, Lei ;

Sun, Miao ;

Li, Chenying ;

Nachtergaele, Sigrid ;

Wang, Yungui ;

Hu, Chao ;

Ferchen, Kyle ;

Greis, Kenneth D. ;

Jiang, Xi ;

Wei, Minjie ;

Qu, Lianghu ;

Guan, Jun-Lin ;

He, Chuan ;

Yang, Jianhua ;

Chen, Jianjun .

NATURE CELL BIOLOGY, 2018, 20 (03) :285-+

[97] Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies [J].

Huang, Shengkang ;

Wang, Xinyu ;

Wang, Yu ;

Wang, Yajing ;

Fang, Chenglong ;

Wang, Yazhuo ;

Chen, Sifei ;

Chen, Runkai ;

Lei, Tao ;

Zhang, Yuchen ;

Xu, Xinjie ;

Li, Yuhua .

MOLECULAR CANCER, 2023, 22 (01)

[98] Chemical Inhibitors Targeting the Oncogenic m6A Modifying Proteins [J].

Huang, Yue ;

Xia, Wenyang ;

Dong, Ze ;

Yang, Cai-Guang .

ACCOUNTS OF CHEMICAL RESEARCH, 2023, 56 (21) :3010-3022

[99] Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia [J].

Huang, Yue ;

Su, Rui ;

Sheng, Yue ;

Dong, Lei ;

Dong, Ze ;

Xu, Hongjiao ;

Ni, Tengfeng ;

Zhang, Zijie Scott ;

Zhang, Tao ;

Li, Chenying ;

Han, Li ;

Zhu, Zhenyun ;

Lian, Fulin ;

Wei, Jiangbo ;

Deng, Qiangqiang ;

Wang, Yungui ;

Wunderlich, Mark ;

Gao, Zhiwei ;

Pan, Guoyu ;

Zhong, Dafang ;

Zhou, Hu ;

Zhang, Naixia ;

Gan, Jianhua ;

Jiang, Hualiang ;

Mulloy, James C. ;

Qian, Zhijian ;

Chen, Jianjun ;

Yang, Cai-Guang .

CANCER CELL, 2019, 35 (04) :677-+

[100] Rational Design and Optimization m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents [J].

Huff, Sarah ;

Kummetha, Indrasena Reddy ;

Zhang, Lingzhi ;

Wang, Lingling ;

Bray, William ;

Yin, Jiekai ;

Kelley, Vanessa ;

Wang, Yinsheng ;

Rana, Tariq M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (15) :10920-10937

← 5 6 7 8 9 10 11 12 13 14 →